Business context and reporting period
Filing identity: The supplied filing is Quintiles Transnational Holdings Inc.’s Form 10-K for the fiscal year ended December 31, 2014, not a filing by IQVIA Holdings Inc. It reports annual results, with unaudited fourth-quarter comparisons also provided.
Quintiles provided biopharmaceutical development and commercial outsourcing services through Product Development and Integrated Healthcare Services. It reported operations in approximately 100 countries and about 32,600 employees. Product Development generated 74.4% of 2014 service revenue; Integrated Healthcare Services generated 25.6%.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Service revenue | $4.166 billion | $3.808 billion |
| Total revenue, including reimbursed expenses | $5.460 billion | $5.100 billion |
| Operating income | $590.4 million | $462.3 million |
| Net income attributable to shareholders | $356.4 million | $226.6 million |
| Diluted EPS | $2.72 | $1.77 |
| Cash from operating activities | $431.8 million | $393.4 million |
| Capital expenditures | $82.7 million | $88.3 million |
| Cash and cash equivalents at year-end | $867.4 million | $778.1 million |
| Total debt and capital leases | $2.306 billion | $2.061 billion |
| Total shareholders’ deficit | $704.0 million | $667.5 million |
Service revenue grew 9.4% reported and 10.1% at constant currency. Operating margin on service revenue was approximately 14.2%, versus 12.1% in 2013. Service costs were 64.4% of service revenue, down from 64.9%. Operating cash flow less capital expenditures was approximately $349.1 million, compared with $305.0 million.
Product Development revenue rose 6.1% to $3.098 billion; segment operating margin increased to 20.8% from 19.3%. Integrated Healthcare Services revenue rose 20.2% to $1.068 billion, while segment operating margin improved to 6.1% from 4.7%. These results include acquisitions and foreign-exchange effects. Total 2014 revenue includes $1.294 billion of reimbursed expenses, which are pass-through costs with little to no profit.
At year-end, current assets were $2.146 billion and current liabilities were $1.472 billion, a current ratio of approximately 1.46. Cash included $210.9 million held in the United States; most foreign subsidiary earnings were considered indefinitely reinvested abroad. Net debt, using reported debt and cash, was approximately $1.44 billion. The filing states that the company was in compliance with debt covenants.
Fourth quarter: Service revenue was $1.064 billion, versus $1.004 billion in Q4 2013; operating income was $158.9 million versus $127.0 million; net income attributable to shareholders was $88.4 million versus $73.0 million; diluted EPS was $0.69 versus $0.55.
Material changes versus the prior comparable period
- Net new business increased 14% to $5.602 billion, and year-end backlog increased 14% to $11.244 billion from $9.855 billion. The filing says $7.593 billion of 2014 year-end backlog was not expected to generate revenue in 2015.
- Integrated Healthcare Services rebounded from a 7.8% revenue decline in 2013, supported by North American and Japanese commercial services, real-world research and the Encore acquisition. Product Development growth was partly offset by the wind-down of a large project.
- Net income attributable to shareholders rose 57%, aided by operating growth and lower interest expense. The effective tax rate was 29.9%, compared with 29.7%.
- Cash from operations improved by $38.4 million. Cash used in investing activities declined to $173.1 million, mainly reflecting lower acquisition spending. Financing activities used $130.3 million, including $415.1 million of share repurchases.
- Debt increased, including a $275 million receivables-financing term loan. The company used its proceeds in part to repay revolving-credit borrowings and $25 million of term debt.
Outlook, commentary, risks and unusual items
- Management expected outsourced clinical development services to grow 6%–8% annually from 2014 to 2017 and expressed a similar expectation for outsourcing across Integrated Healthcare Services. These are market expectations, not company-specific revenue or earnings guidance; the filing provides no clear quantified company financial guidance.
- Management cited a $30 million restructuring plan approved in February 2015, with actions expected during 2015–2016. In 2014, restructuring charges were $9.0 million; the company estimated annualized savings of $20–$25 million from its 2014 plan.
- The July 2014 Encore acquisition cost approximately $91.5 million net of acquired cash. Acquisition activity also included Novella in 2013. In 2014, a reduction in estimated contingent consideration contributed approximately $8.6 million of income, and a securities sale generated an approximately $5.0 million gain.
- The company repurchased shares for approximately $415.1 million during 2014, including separate transactions with shareholders; it did not pay common dividends in 2014. Management said liquidity, operating cash flow and available credit facilities were expected to fund operations and obligations for at least 12 months.
- Key disclosed risks include customer termination or delay of contracts, backlog conversion and scope changes, pricing and cost overruns, competition, foreign-exchange exposure, cyber and patient-data security, clinical-trial and product liability, regulatory compliance, acquisition integration, and substantial debt. Most customer contracts can be terminated on 30–90 days’ notice, and backlog is not guaranteed revenue.
- Approximately $1.1 billion of variable-rate debt was unhedged at year-end; a 0.25 percentage-point rate change was estimated to affect annual interest expense by about $3.5 million. A 10% change in average foreign-exchange rates was estimated to affect 2014 pretax income by about $40.5 million.
- Goodwill and net intangible assets totaled $744.7 million, about 22.5% of total assets; management reported no impairment indication in its annual review. The auditor and management concluded internal control over financial reporting was effective.
Important facts for investors to verify
- Confirm the issuer: this filing is for Quintiles Transnational Holdings Inc., not IQVIA Holdings Inc.
- Review the quality and timing of backlog conversion, including cancellations, delays, and the large portion not expected to convert to revenue in 2015.
- Assess whether segment growth and margin improvement persist, particularly in Integrated Healthcare Services, and separate acquisition effects from organic performance.
- Examine debt maturities, variable-rate exposure, covenant headroom, and dependence on foreign cash that may be costly to repatriate.
- Evaluate the cost, timing and realized savings of restructuring, and the returns from acquisitions and risk-sharing investments.